At 8.7% CAGR, the Asia Pacific Structural Heart Market is Projected to be Worth US$ 4,374.55 million by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific structural heart market was valued at US$ 2,649.67 million in 2022 and is expected to reach US$ 4,374.55 million by 2028, registering a CAGR of 8.7% from 2022 to 2028. Availability of innovative structural heart services and rise in the number of cardiovascular diseases and training programs are the factors attributed to the Asia Pacific structural heart market expansion.

The number of interventional structural heart disease (SHD) procedures, such as transcatheter valve procedures, has increased significantly in recent years, triggering the need for well-founded knowledge about optimal anatomical spatial orientation during these procedures. This has led to the development of new procedural capabilities and technologies in periprocedural planning. Hybrid fusion imaging (FI) combines multiple imaging modalities, mainly based on multislice spiral computed tomography (MSCT) and echocardiography, with fluoroscopy. Ongoing developments in machine learning and artificial intelligence (AI) facilitate the routine use of individualized segmented 3D heart models that allow for multiple combinations of different imaging modalities. As AI enables computers to perform tasks at a greater speed and with potentially better precision than humans, risk stratification and outcome aspects can be optimized in the future. The application of computer modeling, 3D printing, and AI has already led to transformations in procedure planning and physician education on SHD. These technologies also promise unlimited possibilities. With further research and development, AI can advance precision medicine at every step, including diagnosis, treatment stratification and device selection, procedure delivery and guidance, and post-procedure/discharge monitoring and rehabilitation. The prevalence of cardiovascular diseases is rising in the country. For instance, in India, KIMS hospital provides services for the structural heart in the south Indian region. Most of the people in this region chew or smoke tobacco, and the incidence of structural heart disease is increasing in this region. South and Southeast Asia also reported higher mortality rates. Thus, with the rising incidence of structural heart diseases in the abovementioned regions, the market players are likely to grab significant opportunities to offer effective products.

On the contrary, high cost of procedures systems hampers the Asia Pacific structural heart market.  

Based on product, the Asia Pacific structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held 40.3% share of Asia Pacific structural heart market in 2022, amassing US$ 1,067.15 million. It is projected to garner US$ 1,787.33 million by 2028 to expand at 9.0% CAGR during 2022–2028. 

Based on procedure, the Asia Pacific structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held 45.7% share of Asia Pacific structural heart market in 2022, amassing US$ 1,210.82 million. It is projected to garner US$ 2,058.26 million by 2028 to expand at 9.2% CAGR during 2022–2028.

Based on end user, the Asia Pacific structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held 49.2% share of Asia Pacific structural heart market in 2022, amassing US$ 1,302.42 million. It is projected to garner US$ 2,201.03 million by 2028 to expand at 9.1% CAGR during 2022–2028.

Based on country, the Asia Pacific structural heart market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 28.8% share of Asia Pacific structural heart market in 2022. It was assessed at US$ 762.05 million in 2022 and is likely to hit US$ 1,296.18 million by 2028, exhibiting a CAGR of 9.3% during 2022–2028.      

Key players operating in the Asia Pacific structural heart market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, and Lepu Medical Technology Beijing Co Ltd, among others.   

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com